Clearside Biomedical (NASDAQ:CLSD) will issue its quarterly earnings data after the market closes on Tuesday, March 12th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter.
Shares of Clearside Biomedical stock opened at $1.40 on Tuesday. The company has a quick ratio of 4.59, a current ratio of 4.59 and a debt-to-equity ratio of 0.22. The company has a market cap of $47.72 million, a P/E ratio of -0.60 and a beta of -1.30. Clearside Biomedical has a 52 week low of $0.99 and a 52 week high of $15.33.
CLSD has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. downgraded Clearside Biomedical from an “overweight” rating to an “underweight” rating in a report on Monday, November 5th. Cowen restated a “hold” rating on shares of Clearside Biomedical in a report on Tuesday, January 22nd. ValuEngine downgraded Clearside Biomedical from a “buy” rating to a “hold” rating in a report on Thursday, January 24th. Stifel Nicolaus restated a “hold” rating and set a $4.00 target price (down previously from $20.00) on shares of Clearside Biomedical in a report on Monday, November 5th. Finally, Janney Montgomery Scott set a $4.00 target price on Clearside Biomedical and gave the company a “buy” rating in a report on Tuesday, November 6th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. Clearside Biomedical has an average rating of “Hold” and an average price target of $11.28.
ILLEGAL ACTIVITY WARNING: This piece was posted by Fairfield Current and is owned by of Fairfield Current. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.fairfieldcurrent.com/news/2019/03/05/clearside-biomedical-clsd-set-to-announce-quarterly-earnings-on-tuesday.html.
About Clearside Biomedical
Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema.
Read More: Stop Order
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.